• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    The genomic landscape of breast cancer based on ctDNA analysis: Data from the plasmaMATCH trial

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Kingston, B
    Bye, H
    Hubank, M
    Walsh, G
    Swift, C
    Beaney, M
    Kilburn, L
    Kernaghan, S
    Wardley, Andrew M
    Macpherson, I
    Baird, RD
    Roylance, R
    Wilkinson, K
    Garcia-Murillas, I
    Bliss, JM
    Turner, N
    Ring, A
    plasma, MTMG
    Show allShow less
    Affiliation
    The Institute of Cancer Research and The Royal Marsden NHS FT, London
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Background: Circulating tumor DNA (ctDNA) is found in the plasma of over 90% of patients with advanced breast cancer (BC). ctDNA analysis can establish the current genomic profile of an individual's cancer and identify potentially targetable mutations. The genomic landscape of advanced BC and clinical associations has yet to be fully defined. This analysis describes the genomic landscape of ctDNA in patients screened for the UK plasmaMATCH study. Methods: The plasmaMATCH trial was an open-label, multi-centre, multi-cohort platform trial, consisting of ctDNA testing in ~1000 patients with advanced BC. The trial consists of parallel treatment cohorts (Cohorts A-E) with therapies matched to mutations identified in ctDNA testing. The genomic landscape of ctDNA in advanced BC was prospectively analysed for hotspot PIK3CA,AKT1, HER2 and ESR1 mutations using digital droplet PCR (ddPCR, Bio-Rad), and using an error-corrected 73-gene targeted panel (Guardant360, Guardant Health) prospectively from part-way through the trial, and retrospectively for the remaining patients. Results: Entry into ctDNA testing for Cohorts A-D was closed on 26/Apr/2019, at which time 1044 patients had been registered and 1025 tested with ddPCR. 800 patients had targeted panel ctDNA sequencing (364 prospective, 436 retrospective) (Table 1). Targeted sequencing identified a somatic alteration in 92.9% of patients (743/800). The most frequent mutations were TP53 (44.1%), PIK3CA (34.9%), ESR1 (33.1%), GATA3 (11.0%) and ARID1A (7.8%). ESR1 (33.1%) and KRAS (4.1%) alterations occurred at higher frequency in ctDNA compared to a metastatic tissue sequencing series (q<0.0001, q<0.001, respectively). Five genes had different mutation frequency by tumor subtype. Mutations in ERBB2 were enriched in human epidermal growth factor (HER2) amplified disease (13.5%, q = 0.02), mutations in PIK3CA, ESR1 and GATA3 in hormone receptor positive (HR+) HER2 non-amplified disease (q=0.0001, q<0.0001 and q<0.0001, respectively), and TP53 in triple negative disease (q<0.0001). PIK3CA (22.6%) and ERBB2 (17.6%) frequently had multiple mutations per patient. In HR+ BC, recurrent novel second hotspot mutations occurred in PIK3CA at APOBEC mutagenesis sites. Comparison of ctDNA results with paired tissue sequencing data will be presented. Conclusions: Targeted ctDNA sequencing identified distinct genomic profiles of pre-treated advanced BC. ERBB2 mutations are common in HER2 amplified advanced BC, with recurrent second novel mutations in PIK3CA common in HR+ BC.
    Citation
    Kingston B, Bye H, Hubank M, Walsh G, Swift C, Beaney M, et al. Abstract GS3-07: The genomic landscape of breast cancer based on ctDNA analysis: Data from the plasmaMATCH trial. Cancer Research. 2020;80(4):GS3-07-GS3-.
    Journal
    Cancer Research
    URI
    http://hdl.handle.net/10541/623111
    DOI
    10.1158/1538-7445.sabcs19-gs3-07
    PubMed ID
    No PMID
    Additional Links
    https://dx.doi.org/10.1158/1538-7445.sabcs19-gs3-07
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1158/1538-7445.sabcs19-gs3-07
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.